Zenas BioPharma (NASDAQ:ZBIO) Given “Buy” Rating at HC Wainwright

Zenas BioPharma (NASDAQ:ZBIO)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report issued on Wednesday, MarketBeat Ratings reports. They presently have a $44.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 60.34% from the stock’s current price.

A number of other equities analysts also recently commented on the stock. Weiss Ratings downgraded shares of Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 9th. Guggenheim reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Zenas BioPharma in a research report on Friday, August 14th. Citigroup reaffirmed a “buy” rating on shares of Zenas BioPharma in a research report on Wednesday, June 3rd. Wedbush reiterated an “outperform” rating and issued a $45.00 target price on shares of Zenas BioPharma in a research note on Friday, August 14th. Finally, Morgan Stanley upped their price objective on shares of Zenas BioPharma from $22.00 to $32.00 and gave the company an “equal weight” rating in a report on Friday, August 14th. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $45.71.

Zenas BioPharma Trading Up 2.5%

Shares of ZBIO traded up $0.68 during midday trading on Wednesday, hitting $27.44. The stock had a trading volume of 201,469 shares, compared to its average volume of 816,314. Zenas BioPharma has a 1 year low of $13.50 and a 1 year high of $44.60. The firm has a market cap of $1.79 billion, a PE ratio of -3.05 and a beta of -1.04. The company has a debt-to-equity ratio of 1.57, a current ratio of 9.93 and a quick ratio of 9.93. The stock’s 50 day moving average is $31.47 and its 200 day moving average is $25.08.

Zenas BioPharma (NASDAQ:ZBIO) last announced its earnings results on Wednesday, August 12th. The company reported ($1.77) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.65). The firm had revenue of $1.00 million for the quarter, compared to analyst estimates of $15.00 million. As a group, analysts forecast that Zenas BioPharma will post -5.81 EPS for the current fiscal year.

Institutional Investors Weigh In On Zenas BioPharma

Hedge funds have recently modified their holdings of the business. Quantbot Technologies LP acquired a new stake in shares of Zenas BioPharma in the second quarter valued at about $49,000. ProShare Advisors LLC purchased a new stake in shares of Zenas BioPharma in the fourth quarter valued at about $211,000. Jupiter Topco LLC purchased a new stake in shares of Zenas BioPharma in the second quarter valued at about $201,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Zenas BioPharma in the second quarter valued at about $204,000. Finally, Sei Investments Co. purchased a new stake in shares of Zenas BioPharma in the first quarter valued at about $242,000.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for patients with immune-mediated diseases. The company’s research and development efforts are centered on therapies that modulate the immune system and address conditions with significant unmet medical needs.

Zenas’ lead investigational product is obexelimab, an immune-modulating monoclonal antibody designed to inhibit the activity of certain B cells without broadly depleting them. The company is evaluating obexelimab in autoimmune and inflammatory diseases, including IgG4-related disease and systemic lupus erythematosus.